期刊文献+

葡萄球菌对利奈唑胺等抗菌药物的耐药性分析 被引量:5

下载PDF
导出
摘要 目的分析无锡市2家医院葡萄球菌耐药现状,评价利奈唑胺、奎奴普丁/达福普丁等新型抗革兰阳性球菌药物的抗菌活性。方法收集2008年1月到2009年4月无锡市人民医院和无锡市第二人民医院的葡萄球菌1 342株,采用琼脂稀释法测定抗菌药物的最低抑菌浓度(M IC)。结果1 342株受检菌中金黄色葡萄球菌为534株,凝固酶阴性葡萄球菌809株。金黄色葡萄球菌和凝固酶阴性葡萄球菌中耐甲氧西林菌株分别占65.9%和85.3%。利奈唑胺、奎奴普丁/达福普丁对上述菌株均具有高度的抗菌活性;其中利奈唑胺的活性与万古霉素(VAN)相当,耐药率均为0。利奈唑胺、奎奴普丁/达福普丁对葡萄球菌的M IC值多分布在2 mg/L和0.5 mg/L。结论利奈唑胺和奎奴普丁/达福普丁对葡萄球菌,包括多重耐药菌具有高度抗菌活性,在治疗过程中要监测有无耐药株出现。
出处 《检验医学》 CAS 北大核心 2009年第11期834-836,共3页 Laboratory Medicine
  • 相关文献

参考文献10

  • 1Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates [J]. J Antimicrob Chemother, 2001,47( 1 ) :77-81.
  • 2Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid:a European inter-country comparison [J].J Antimicrob Chemother,2001,48 (1):47-52.
  • 3Chang S , Sievert DM , Hageman JC , et al. Infection with vancomycin-resistant Staphylococcus aureus con- taining the vanA resistance gene[J]. N Engl J Med, 2003,348(14) : 1342-1347.
  • 4保勇,喻华,杨永长.利奈唑胺对革兰阳性球菌的体外抗菌活性研究[J].实验与检验医学,2009,27(1):23-24. 被引量:15
  • 5Shinabarger DL, Marotti KR, Murray RW,et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions [ J]. Antimicrob Agents Chemother, 1997,41 ( 10 ) : 2132-2136.
  • 6刘昱东,王辉,杜娜,孙宏莉,徐英春,杨启文,陈民钧,谢秀丽.利奈唑胺、替加环素、达托霉素、头孢吡普等抗菌药物对MRSA的抗菌活性[J].中国感染与化疗杂志,2008,8(1):10-14. 被引量:48
  • 7Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001 :SENTRY Antimicrobial Surveillance Program [J]. Ann Pharmacother, 2003,37 ( 6 ) : 769 - 774.
  • 8Barriere JC, Berthaud N, Beyer D, et al. Recent developments in streptogramin research [ J ]. Curr Pharm Des, 1998,4(2) : 155-180.
  • 9Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin[J]. Clin Pharmacokinet, 2004, 43 (4) :239-252.
  • 10Bouanchaud DH. In-vitro and in-vivo antibacterial activity of quinuprisitin/dalfopristin [ J ]. J Antimicrob Chemother, 1997,39( Suppl A) : 15-21.

二级参考文献16

  • 1熊剑文,裴云,冯瑞祥,李亚舒,杨成芳.耐甲氧西林葡萄球菌的耐药性监测[J].南京军医学院学报,2003,25(4):223-225. 被引量:1
  • 2朱德妹,汪复,张婴元.2003年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(1):4-12. 被引量:147
  • 3朱德妹,汪复,张婴元.2004年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(4):195-200. 被引量:227
  • 4Lowy FD. Staphylococcus aureus infections[J]. N Engl J Med, 1998, 339(8): 520-532.
  • 5Chang S , Sievert DM, Hageman JC, et, al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene[J]. N Engl J Med, 201)3, 348(14): 1342-1347.
  • 6Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement[S]. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania: CLSI, 2006 :1-150.
  • 7Jonas D, Grundmann H, Hartung D, et al. Evaluation of the mecA femB duplex polymerase chain reaction for detection of methieillin-resistant Staphylococcus aureus [J]. Eur J Clin Microbiol Infect Dis, 1999,18(9):643-647.
  • 8Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of ngecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-posinve clinical isolates from Greek hospitals[J]. Antimicroh Agents Chemother, 2006, 50(9):3166-3169.
  • 9Jones R, Deshpandel LM, Mutnick AM, et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci [J]. J Antimicrob Chemotherapy, 2002, 50(6):915-932.
  • 10Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillinresistant S. aureus infection among patients in the emergency department[J]. N Engl J Med, 2006, 355(7): 666-674.

共引文献61

同被引文献57

  • 1马琳.金黄色葡萄球菌感染性皮肤病的外用抗生素选择[J].实用皮肤病学杂志,2009,2(1):20-22. 被引量:6
  • 2王从容.抗菌新药——利奈唑胺[J].中国医院药学杂志,2006,26(5):614-616. 被引量:23
  • 3王燕,李苏利,李杨.我院2005年临床分离菌菌群分布及耐药分析[J].华北国防医药,2007,19(1):47-49. 被引量:13
  • 4Babini GS, Livermore DM . Antimicrobial resistance amongst Kleh- siella spp. collected from intensive care units in Southern and Western Europe in 1997 - 1998 [J]. Antimicrob Chemother, 2000;45 : 183 - 189.
  • 5Gadepalli R, Dhawan B, Mohanty S, et al. Mupirocin resistance in Staphylococcus aureus in an Indian hospital[J]. Diagn Microbiol Infect Dis, 2007,58 ( 1 ) : 125 - 127.
  • 6Beekmarm S E, Gilbert D N, Polgreen P M, et al. Toxicity of extended courses of linezolid: results of an infectious diseases society of America emerging infections network survey[J]. Diag Microbiol Infect Dis, 2008, 62(4): 407-410.
  • 7Vergidis P I, Falagas M blood-stream infections[J] 32(Suppl 1): $60-$65. E. New antibiotic agents for Int J Antimicrob Agents, 2008,.
  • 8Mutnick A H, Enne V, Jones R N. Linezolid resistancesince 2001: Sentry antimicrobial surveillance program[J]. Ann Pharmacother, 2003, 37(6): 769-774.
  • 9Nadege B N, Laurent M, Brigitte C, et al. Dose dependence of emergence of resistance to linezolid in Enterocoecus faecalis in[J]. Jlnfect Dis, 2007, 1(10): 1480-1488.
  • 10Potoski B A, Adams J, Clarke L, et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci[J]. Clin Infect Dis, 2006, 43(3): 165-17 l.

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部